Chemomab Therapeutics’ CM-101 shows clinical potential in sclerosing cholangitis

Chemomab Therapeutics announced publication of proteomic analyses that further demonstrate the role of the soluble protein CCL24 in driving pathologies associated with the rare fibrotic liver disease primary sclerosing cholangitis. The new studies reinforce existing evidence showing that Chemomab’s first-in-class CCL24-neutralizing antibody CM-101 can interrupt these destructive processes. The studies confirmed the exclusive association of CCL24 with fundamental PSC mechanisms, with no similar association seen with two other related proteins sharing the same receptor, emphasizing CCL24’s unique potential as a target for PSC therapies. CM-101 has Orphan Drug designation for PSC in the U.S. and the European Union and was recently awarded Fast Track designation by the FDA for the treatment of PSC in adults.